Insight

Paolo Tarantino: The most discussed side effect of T-DXd is ILD

Collage photo of Paolo Tarantino and Naoto T Ueno

May 15, 2025, 07:00

Paolo Tarantino: The most discussed side effect of T-DXd is ILD

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post by Naoto T Ueno, Director of the University of Hawaii Cancer Center, adding:

“The most discussed side effect of T-DXd is ILD. Yet the most frequent ones, and the ones that most often lead to dose reduction of T-DXd, are fatigue and emesis. Now confirmed by PRO. Always remember to use adequate anti-emetic prophylaxis (3-drug regimen) + olanzapine when needed.”

Quoting Naoto T Ueno‘s post:

“The DESTINY-Breast04 study highlights a critical issue—persistent, subtle nausea and fatigue that patients experience compared to standard chemotherapy. Read the papers for details. That’s why patients have shared concerns about the impact of Enhertu (T-DXd) on quality of life.”

Title: Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC

Authors: Naoto T Ueno, Francesco Cottone, Kyle Dunton, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Aleix Prat, Junji Tsurutani, Yeon Hee Park, Hope S Rugo, Binghe Xu, Fatima Cardoso, Zahi Mitri, Reshma Mahtani, Cecilia Orbegoso Aguilar, Feng Xiao, Nadia Harbeck, David A Cameron, Shanu Modi

You can read the Full Article on Journal of The Oncologist.

Paolo Tarantino

Aleix Prat Binghe Xu cancer Cecilia Orbegoso Aguilar David A Cameron Eriko Tokunaga Fatima Cardoso Feng Xiao Francesco Cottone Hope S. Rugo Joohyuk Sohn Junji Tsurutani Kyle Dunton Nadia Harbeck Naoto T Ueno OncoDaily Oncology Reshma Mahtani Shanu Modi Toshinari Yamashita William Jacot Yeon Hee Park Zahi Mitri

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot